For the first time the FDA has approved a cancer treatment based on tumor biomarkers rather than the site in the body where a tumor originated. The agency’s action brings cancer therapy a step closer to precision medicine approaches that consider individual patient characteristics in treatment choices.
Pembrolizumab’s new indication is for adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors or colorectal cancer that has progressed despite treatment with fluoropyrimidine, oxaliplatin, or irinotecan.
Voelker R. Precision Approach in Cancer Care. JAMA. 2017;318(1):20. doi:10.1001/jama.2017.7641
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: